Our Services

Current Research Studies

ALECARDIO

Evaluates the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)  Mark Bieniarz, MD Principal Investigator


Click here To Participate

ANALYZE-ST

ANALYZE-ST: Tests the accurary of the ST monitoring feature on Implantable Cardioverter Defibrillator (ICD). Sean Mazer, MD Principal Investigator


Click here To Participate

AVOID-HF

This study utilizes Aquapheresis Versus Intravenous Diurectics to compare these two methods of fluid removal from the heart.  Robert Orchard, MD Principal Investigator


Click here To Participate

CANTOS

Evaluates whether the drug canakinumab reduces further events in patients who have had previous Myocardial Infarctions.   Robert Orchard, MD Principal Investigator


Click here To Participate

On-X VALVE

Compares the On-X valve on low dose anticoagulation to concomitant groups of On-X valves receiving standard coumadin/aspirin therapy and to also drive FDA objective performance criteria (OPC).  Paul Levy, MD Principal Investigator


Click here To Participate

PARADIGM

Evaluates the effectiveness and safety of a Newly Devised Drug in Patients with Chronic Heart Failure.  Robert Orchard, MD Principal Investigator


Click here To Participate

PRADAXA-GI

Pradaxa is an FDA approved blood thinning medication.  Some patients who take Pradaxa develop gastrointestinal symptoms (GIS).  This study evaluates the effectiveness of two kinds of treatment for GIS.  Jay Tiongson, MD Principal Investigator


Click here To Participate

PROMISE

Compares different heart tests in identifying heart disease in patients with symptoms, and to attempt to reduce future problems with the heart. Brendan Cavanaugh, MD Principal Investigator


Click here To Participate

REDUCE-IT

This study evaluates the effect of AMR101 on cardiovascular health and mortality in Hypertriglyceridemic patients with CAD or a high risk for CAD. Robert Orchard, MD Principal Investigator


Click here To Participate

ROADMAP

Conducting risk assessment and comparative effectiveness of Left Ventricular Assist Device (LVAD) to medical management in ambulatory heart failure patients.  Sean Mazer, MD Principal Investigator


Click here To Participate

SHIELD 2

The main purpose of this study is to see if Azimilide Dihydrochloride (not yet approved FDA drug) can help patients to have fewer hospitalizations/emergency department visits.  Ross Downey, MD Principal Investigator


Click here To Participate

St. Jude's Leads Assessment

A study involving the Riata®/Riata® ST silicone endocardial leads made by St. Jude Medical.  This study does not involve any investigational product (medical device) or procedures.


Click here To Participate

TAXUS - Liberte

Post approval study of a Paclitaxel-Eluting Coronary Stent System.  Robert E. Federici, MD Principal Investigator


Click here To Participate

UPCOMING STUDIES

ABSORB: A stent study for patients requiring intervention.  Robert Federici, MD Principal Investigator

EVOLVE-II: To compare the safety and effectiveness of two drug-eluting stents in the treatment of coronary artery disease.  Geoffrey Kunz, MD Principal Investigator

PARACHUTE IV: This Implant is intended to reduce the occurrence of death and hospitalization for heart failure by isolation of the malfunctioning portion of the left ventricle in symptomatic heart failure patients with EF<35% due to myocardial infarction in the LAD territory.  Mark Bieniarz, MD Principal Investigator

SJM MultiPoint Pacing (MPP): This study is to evaluate safety and efficacy of the Quadripolar cardiac resynchronization therapy defibrillator (CRT-D) device with MultiPoint™ Pacing (MPP) feature in stimulating the left lower chamber of the heart in patients indicated for cardiac resynchronization therapy. 


Click here To Participate

WARFARIN

WARFARIN: Attempts to reduce the adverse effects of this popular blood thinner by looking at genetic variations Principal Investigator Ross Downey, MD


Click here To Participate

X-VeRT

 A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose-adjusted oral vitamin K antagonists (VKA)for the prevention of cardiovascular events in subjects with nonvalvular atrial fibrillation scheduled for cardioversion

      


Click here To Participate

Find it Fast



NMHI IN THE NEWS

Participate in a Research Study

Click here to let us know that you are interested in participating in a future research study.